Vorinostat
A recent study suggested that vorinostat also possesses some activity against recurrent glioblastoma multiforme, resulting in a median overall survival of 5.7 months (compared to 4–4.4 months in earlier studies). Further brain tumor trials are planned in which vorinostat will be combined with other drugs.
Pleomorphic xanthoastrocytoma
Among people with PXA who were able to have their tumors completely resected during surgery, there is a long-term survival rate of 90%. After incomplete resection, the long-term survival rate is higher than 50%. Morbidity is determined by the type and evolution of the tumor, with high-graded anaplastic tumors causing more fatalities.